Source: Annual Congress 2006 - Recent advances in the basic mechanisms of allergic asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Amenomori, H. Matsuura, M. Seki (Yokohama, Japan). The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor. Eur Respir J 2006; 28: Suppl. 50, 2533

Member's Comments

No comment yet.

Related content which might interest you: In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011 Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004 Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD Source: Eur Respir J, 52 (5) 1801074; 10.1183/13993003.01074-2018 Year: 2018 Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 42s Year: 2001 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010